Navigation Links
Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
Date:6/28/2010

p us with the future successful development of AEZS-108 in a number of different LHRH expressing cancers."

President and Managing Director of Almac Diagnostics, Professor Paul Harkin , said "We are very pleased to collaborate with Aeterna Zentaris on this exciting project. The plan to develop a companion diagnostic for AEZS-108 shows Aeterna Zentaris's clear commitment to personalized medicine, which will provide this compound with the best opportunity for success "

About AEZS-108

AEZS-108, a doxorubicin LHRH receptor targeted conjugate, is currently in a Phase 2 trial in advanced ovarian and endometrial cancer. Positive final results in ovarian cancer were disclosed at this year's American Society of Clinical Oncology (ASCO) meeting*, while final results in endometrial cancer are expected by year-end. AEZS-108 has been granted orphan-drug designation by the U.S. Food and Drug Administration and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer.

An Investigational New Drug (IND) in the U.S. is in place for the treatment of bladder cancer.

Additional clinical studies in hormone-resistant prostate cancer and other cancer types are being planned. There may be benefits during the regulatory review process from the medical and scientific logic of this personalized treatment approach to patient selection and possibly have value in reimbursement considerations.

    * Asco poster presentation: abstract #5035 entitled,
        "Phase 2 study of AEZS-108, a targeted cytotoxic LHRH analog, in
        patients with LHRH receptor positive platinum resistant ovarian
        cancer.

About Almac


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... Research and Markets ( ... "Global Biotechnology Reagents Market 2014-2018" report ... Biotechnology reagents are chemical compounds or ... detect and examine another substance to provide a ... to prepare, collect, and examine specimens from the ...
(Date:9/22/2014)... (CTCs) in a mouse model of pancreatic cancer identified ... CTCs, including significant differences from the primary tumor that ... In their study reported in the Sept. 25 issue ... General Hospital (MGH) Cancer Center identified several different classes ... prove to be targets for improved treatment of the ...
(Date:9/22/2014)... Researchers have discovered a way to create a highly ... graphene sheets. The imperfections have unique electronic properties that ... to absorbed gas molecules by 300 times. , The ... Nature Communications . , Amin Salehi- Khojin, asst ... with Mohammad Asadi, graduate student and Bijandra Kumar, post ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... of investigational sustained follicle stimulant achieves similar efficacy to ... week period in Phase III Study , , ... SGP ) today announced results from the Phase III ... corifollitropin alfa, first in the class of sustained follicle ...
... a subsidiary of Eisai Corporation of North America, announced ... express and develop therapeutic monoclonal antibodies for the potential ... , , Under the terms of the agreement, ... technology and its expertise to produce and develop a ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... device and methods for linking biological agents to labels for ... as In-Line labeling, was developed for the production of radiolabeled ... A study published today in the July 2009 issue ...
Cached Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
(Date:9/22/2014)... of cut grass in recent years has been identified ... research says the aroma also summons beneficial insects to ... the plant signals the environment via the emission of ... queue for parasitic wasps to come to the plant ... pest insect," said Dr. Michael Kolomiets, Texas A&M AgriLife ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Answer to restoring lost island biodiversity found in fossils 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... at St. Jude Children's Research Hospital have discovered how a ... effects ranging from learning and memory capabilities to glucose production ... called CREB, is a transcription factor—a molecule that binds to ... gene to make the specific protein for which it codes. ...
... provides the most compelling evidence to-date that some dinosaurs ... del Campo track site in Spain's Cameros Basin, contains ... a non-avian therapod dinosaur. , A team led ... La Rioja, Spain, discovered the prints in an area ...
... guys that help bacterial pathogens do their job of infecting ... essence, they knock down the front door of resistance and ... University of California, San Diego (UCSD) School of Medicine have ... YpkA, one of several effectors of the bacteria Yersinia – ...
Cached Biology News:St. Jude study shows genes play an unexpected role in their own activation 2Definitive evidence found of a swimming dinosaur 2How plague-causing bacteria disarm host defense 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: